Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies

被引：1
|
作者：
Szatmari, B. [1 ]
Barabassy, A. [1 ]
Laszlovszky, I. [1 ]
Harsanyi, J. [1 ]
Acsai, K. [1 ]
Burjan, A. [1 ]
Sebe, B. [1 ]
Earley, W. [2 ]
Patel, M. [2 ]
Nemeth, G. [1 ]
机构：
[1] Gedeon Richter Plc, Med Div, Budapest, Hungary
[2] Allergan Pharmaceut Inc, Madison, NJ USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷
关键词：
D O I：
10.1016/j.euroneuro.2018.11.635
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.618
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
    Earley, Willie
    Durgam, Suresh
    Lu, Kaifeng
    Laszlovszky, Istvan
    Debelle, Marc
    Kane, John M.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2017, 32 (06) : 319 - 328
  • [42] Cariprazine for Negative Symptoms of Schizophrenia: Pooled Post Hoc Analysis of 2 Randomized, Double-Blind, Placebo- and Active-Controlled Trials
    Earley, Willie
    Durgam, Suresh
    Debelle, Marc
    Laszlovszky, Istvan
    Lu, Kaifeng
    Nasrallah, Henry
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S233 - S234
  • [43] Cariprazine for negative symptoms of schizophrenia: pooled post hoc analysis of 2 randomized, double-blind, placebo- and active-controlled trials
    Durgam, S.
    Earley, W.
    Lu, K.
    Nemeth, G.
    Laszlovszky, I.
    Szatmari, B.
    Edwards, J.
    Nasrallah, H. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S552 - S552
  • [44] Efficacy and safety of cariprazine in the treatment of bipolar disorder
    Saraf, Gayatri
    Pinto, Jairo Vinicius
    Yatham, Lakshmi N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (17) : 2063 - 2072
  • [45] The efficacy of cariprazine in chronic schizophrenia - post hoc analyses of phase II/III clinical trials
    Falkai, P.
    Dombi, Z.
    Acsai, K.
    Barabassy, A.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2022, 65 : S323 - S323
  • [46] Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone
    Sebe, B.
    Barabassy, A.
    Laszlovszky, I.
    Szatmari, B.
    Harsanyi, J.
    Acsai, K.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S275 - S275
  • [47] Efficacy of cariprazine in negative, cognitive, and social function symptoms in schizophrenia: post hoc analysis of a randomized, controlled trial
    Cutler, A. J.
    Durgam, S.
    Lu, K.
    Laszlovszky, I.
    Szalai, E.
    Edwards, J.
    Earley, W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S551 - S552
  • [48] Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains
    Laszlovszky, I.
    Barabassy, A.
    Szatmari, B.
    Harsanyi, J.
    Szalai, E.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S902 - S903
  • [49] Efficacy of cariprazine in predominant negative symptoms of schizophrenia - post hoc analyses against different comparators
    Szatmari, B.
    Barabassy, A.
    Laszlovszky, I.
    Harsanyi, J.
    Acsai, K.
    Reti-Gyorffy, D.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2018, 48 : S105 - S105
  • [50] Sustained remission with cariprazine treatment: post hoc analysis of a randomized, double-blind, schizophrenia relapse prevention trial
    Correll, C. U.
    Potkin, S. G.
    Durgam, S.
    Cheng, C. T.
    Szatmari, B.
    Laszlovszky, I.
    Saliu, I.
    Earley, W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S935 - S936
12345